Relmada Therapeutics, Inc. RLMD Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares)?
- Relmada Therapeutics, Inc. (RLMD) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 15.6M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
- Relmada Therapeutics, Inc.'s stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 28.5% year-over-year, from 12.1M to 15.6M.
- What does stock options excluded as their inclusion would be anti-dilutive (in shares) mean?
- The number of potential common shares, such as stock options or restricted stock units, excluded from the diluted earnings per share calculation because their inclusion would be antidilutive. This metric helps investors understand the potential future dilution that is currently excluded from standard per-share performance reporting.